Benjamin L. Palleiko

Insider Reports History

Reporting-owner location: Cambridge, MA
Latest reporting-owner signature: /s/ Benjamin L. Palleiko
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Benjamin L. Palleiko

Form 4 holding CHIEF EXECUTIVE OFFICER, Director

KalVista Pharmaceuticals, Inc.

Security class: Restricted Stock Unit
Shares / value: 0
Estimated value: $1,878,760
Report date: 11 Jun 2026
Price: $10.02
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding CHIEF EXECUTIVE OFFICER, Director

KalVista Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 11 Jun 2026
Price: $20.13
Ownership: Direct

Form 4 holding CHIEF EXECUTIVE OFFICER, Director

KalVista Pharmaceuticals, Inc.

Security class: Employee Stock Option
Shares / value: 113,920
Estimated value
Report date: 11 Aug 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding CHIEF EXECUTIVE OFFICER, Director

KalVista Pharmaceuticals, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 0
Estimated value
Report date: 11 Jun 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Benjamin L. Palleiko

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 11 Jun 2026
Transactions: 18
Transaction value: $0
Accepted by SEC: 11 Jun 2026, 16:27
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 21 May 2026
Transactions: 3
Transaction value: -$292,646
Accepted by SEC: 26 May 2026, 19:35
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 May 2026
Transactions: 3
Transaction value: -$30,212
Accepted by SEC: 19 May 2026, 16:03
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 11 May 2026
Transactions: 3
Transaction value: -$88,731
Accepted by SEC: 13 May 2026, 16:25
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 16 Apr 2026
Transactions: 3
Transaction value: -$193,066
Accepted by SEC: 20 Apr 2026, 19:40
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Mar 2026
Transactions: 3
Transaction value: -$107,633
Accepted by SEC: 10 Mar 2026, 18:47
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 21 Feb 2026
Transactions: 3
Transaction value: -$156,197
Accepted by SEC: 24 Feb 2026, 19:44
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Feb 2026
Transactions: 3
Transaction value: -$15,570
Accepted by SEC: 19 Feb 2026, 19:45
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 11 Feb 2026
Transactions: 3
Transaction value: -$52,658
Accepted by SEC: 13 Feb 2026, 16:05
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 16 Jan 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 21 Jan 2026, 16:09
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Dec 2025
Transactions: 3
Transaction value: -$120,424
Accepted by SEC: 09 Dec 2025, 18:16
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 21 Nov 2025
Transactions: 3
Transaction value: -$147,154
Accepted by SEC: 26 Nov 2025, 18:46
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Nov 2025
Transactions: 4
Transaction value: -$64,665
Accepted by SEC: 19 Nov 2025, 16:13
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 11 Nov 2025
Transactions: 3
Transaction value: -$38,438
Accepted by SEC: 13 Nov 2025, 16:28
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Sep 2025
Transactions: 3
Transaction value: -$115,537
Accepted by SEC: 09 Sep 2025, 19:02
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 21 Aug 2025
Transactions: 3
Transaction value: -$144,657
Accepted by SEC: 25 Aug 2025, 19:46
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Aug 2025
Transactions: 4
Transaction value: -$58,141
Accepted by SEC: 19 Aug 2025, 16:26
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 11 Aug 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 13 Aug 2025, 17:29
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 08 Jul 2025
Transactions: 2
Transaction value: -$517,523
Accepted by SEC: 10 Jul 2025, 20:56
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Jun 2025
Transactions: 3
Transaction value: -$103,950
Accepted by SEC: 10 Jun 2025, 17:00
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 21 May 2025
Transactions: 3
Transaction value: -$118,743
Accepted by SEC: 23 May 2025, 16:24
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 May 2025
Transactions: 4
Transaction value: -$45,097
Accepted by SEC: 20 May 2025, 19:28
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Mar 2025
Transactions: 3
Transaction value: -$79,828
Accepted by SEC: 10 Mar 2025, 18:43
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 21 Feb 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 25 Feb 2025, 20:36
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Feb 2025
Transactions: 4
Transaction value: -$50,143
Accepted by SEC: 19 Feb 2025, 20:46
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Dec 2024
Transactions: 3
Transaction value: -$74,363
Accepted by SEC: 09 Dec 2024, 21:08
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Nov 2024
Transactions: 5
Transaction value: -$133,294
Accepted by SEC: 19 Nov 2024, 19:19
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Sep 2024
Transactions: 3
Transaction value: -$89,622
Accepted by SEC: 10 Sep 2024, 20:31
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Aug 2024
Transactions: 5
Transaction value: -$170,769
Accepted by SEC: 21 Aug 2024, 21:25
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Jun 2024
Transactions: 3
Transaction value: -$86,068
Accepted by SEC: 10 Jun 2024, 18:42
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 May 2024
Transactions: 6
Transaction value: -$258,337
Accepted by SEC: 21 May 2024, 17:57
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 06 Mar 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 08 Mar 2024, 16:50
Role: CHIEF EXECUTIVE OFFICER, Director
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Feb 2024
Transactions: 6
Transaction value: -$321,846
Accepted by SEC: 21 Feb 2024, 21:46
Role: CFO, CBO
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 14 Feb 2024
Transactions: 1
Transaction value: -$613,205
Accepted by SEC: 16 Feb 2024, 16:21
Role: CFO, CBO
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 11 Feb 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 13 Feb 2024, 09:23
Role: CFO, CBO
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Nov 2023
Transactions: 5
Transaction value: -$107,047
Accepted by SEC: 21 Nov 2023, 16:31
Role: President, CFO, CBO & Sec'y
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Aug 2023
Transactions: 5
Transaction value: -$140,192
Accepted by SEC: 21 Aug 2023, 20:05
Role: President, CFO, CBO & Sec'y
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 18 May 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 May 2023, 21:33
Role: President, CFO, CBO & Sec'y
Next action: Open filing details

4/A KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Feb 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 May 2023, 21:39
Role: President, CFO, CBO & Sec'y
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 11 Jan 2023
Transactions: 5
Transaction value: -$40,953
Accepted by SEC: 19 May 2023, 21:19
Role: President, CFO, CBO & Sec'y
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Nov 2022
Transactions: 3
Transaction value: -$3,928
Accepted by SEC: 21 Nov 2022, 15:20
Role: CFO, CBO & Secretary
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 Aug 2022
Transactions: 3
Transaction value: -$10,847
Accepted by SEC: 19 Aug 2022, 17:15
Role: CFO, CBO & Secretary
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 17 May 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 19 May 2022, 16:56
Role: CFO, CBO & Secretary
Next action: Open filing details

4 KALV

KalVista Pharmaceuticals, Inc.

Report period: 26 May 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 28 May 2021, 17:25
Role: CFO, CBO & Secretary
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for Benjamin L. Palleiko

Insider Reports Filed by Benjamin L. Palleiko